Investigational Drug Information for Apabetalone
✉ Email this page to a colleague
What is the drug development status for Apabetalone?
Apabetalone is an investigational drug.
There have been 8 clinical trials for Apabetalone.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Familial Primary Pulmonary Hypertension, Atherosclerosis, and Myocardial Ischemia. The leading clinical trial sponsors are Resverlogix Corp, ICON plc, and Medidata Solutions.
There are thirty US patents protecting this investigational drug and three hundred and twelve international patents.
Summary for Apabetalone
| US Patents | 30 |
| International Patents | 312 |
| US Patent Applications | 135 |
| WIPO Patent Applications | 95 |
| Japanese Patent Applications | 19 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 87 |
Recent Clinical Trials for Apabetalone
| Title | Sponsor | Phase |
|---|---|---|
| Apabetalone for Pulmonary Arterial Hypertension | Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Resverlogix Corp | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Phase 2 |
Clinical Trial Summary for Apabetalone
Top disease conditions for Apabetalone
Top clinical trial sponsors for Apabetalone
US Patents for Apabetalone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| apabetalone | ⤷ Try a Trial | Pharmaceutical compositions for substituted quinazolinones | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | Compositions and therapeutic methods for the treatment of complement-associated diseases | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | Anti-inflammatory agents | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | Therapy for promoting cell growth | MOLEAC PTE. LTD. (Singapore, SG) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (South San Francisco, CA) | ⤷ Try a Trial |
| apabetalone | ⤷ Try a Trial | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Apabetalone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| apabetalone | Australia | AU2012330885 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | Canada | CA2851996 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | China | CN103945848 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | Denmark | DK2773354 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | European Patent Office | EP2773354 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | Spain | ES2745471 | 2031-11-01 | ⤷ Try a Trial |
| apabetalone | Hong Kong | HK1201751 | 2031-11-01 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
